Review on lipegfilgrastim
Maja Gasparic, Sophie LeymanTeva Pharmaceuticals Europe BV, European Headquarters, Amsterdam, the NetherlandsHaving read the original Hoggatt et al article1 and the corrigendum published online on August 27, 2015,2 we do not consider the description of lipegfilgrastim to be entirely accurate, and we...
Saved in:
Main Authors: | Gasparic M, Leyman S |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2015
|
Subjects: | |
Online Access: | https://doaj.org/article/71f97796db5a4d8f91a8d2a32e5ba85e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
by: Hoggatt J, et al.
Published: (2015) -
Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
by: Hoggatt J, et al.
Published: (2015) -
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
by: Guariglia R, et al.
Published: (2016) -
Thermosensitive liposomal drug delivery systems: state of the art review
by: Kneidl B, et al.
Published: (2014) -
Application of supercritical antisolvent method in drug encapsulation: a review
by: Kalani M, et al.
Published: (2011)